COMP <GO>
MRNA vs UNH // FORWARD P/E MULTIPLE
Moderna Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MRNA 3
— UNH 11
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $221.72 (-0.47%) • MKT CAP: $88.93B
forward-pe
32.0x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
forward-pe
17.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRNA VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRNA | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.30% | 88.57% | -33.27 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.10% | 11.47% | -45.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.32% | 6.48% | -8.80 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.14% | -63.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -39.90% | 6.46% | -46.36 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.07 | 3.12 | +11.95 | MRNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 56.0 | +1.28 | MRNA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.33 | +0.77 | MRNA | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 32.0x | 17.1x | +14.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $88.93B | $364.66B | -$275.73B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRNA REV | UNH REV | MRNA GROSS % | UNH GROSS % | MRNA FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.94B | $447.57B | 55.3% | 88.7% | -$2.06B | $16.07B |
| FY 2024 | $3.24B | $400.28B | 54.8% | 88.3% | -$4.05B | $20.70B |
| FY 2023 | $6.85B | $371.62B | 44.0% | 89.6% | -$3.43B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRNA // BETA 1.10
UNH // BETA 0.33